Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations
Bioinformatics · 2026
DOI: 10.1093/bioinformatics/btag491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformatics, 2026. Verfasst von Federica Malighetti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy. Hauptthemen laut MEDLINE: Mutation, Neoplasms, Circulating Tumor DNA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Foundation for Cancer Research (AIRC) under MFAG, AIRC fellowship for Italy, Oxiamo ONLUS.
Abstract (Originalsprache)
Motivation Circulating tumor DNA (ctDNA) and clonal hematopoiesis of indeterminate potential (CHIP) are two biologically distinct sources of somatic mutations detectable in blood. While ctDNA captures tumor-intrinsic alterations, CHIP arises from age-related hematopoietic clones and is often considered background noise. Here, we conduct a large-scale, tumor-type–resolved analysis of over 9000 patients with CHIP data and 1500 patients with ctDNA data across solid tumors profiled at Memorial Sloan Kettering Cancer Center. Results Our results reveal that CHIP and ctDNA mutations exhibit non-overlapping, clinically meaningful signals. CHIP mutations, particularly in DNA damage response and epigenetic regulators (e.g. PPM1D, CHEK2, ATM, TP53, ASXL1), are associated with worse overall survival, increased metastatic potential, and site-specific dissemination. ctDNA mutations in canonical oncogenic drivers (e.g. TP53, EGFR, KRAS, STK11) reflect tumor aggressiveness and correlate with poor prognosis and metastasis across multiple cancer types. Joint modeling in lung adenocarcinoma confirms the independent prognostic contributions of both compartments. Additionally, longitudinal clonal analysis links specific CHIP mutations to the emergence of hematologic malignancies under therapeutic pressure. These findings support a dual-compartment model of liquid biopsy, in which tumor- and host-derived mutations jointly inform on cancer risk, progression, and metastatic behavior. Integrating both compartments may enhance the clinical utility of blood-based biomarkers in oncology. Availability All genomic and clinical data used in this study are available through cBioPortal. Summarized outputs and processed results tables are provided in Supplementary Data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.
- Experimental Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Fondazione IRCCS San Gerardo dei Tintori di Monza, Monza, Italy.
ORCID-Profile: Luca Sala, Daniele Ramazzotti
Förderung
- Italian Foundation for Cancer Research (AIRC) under MFAG
- AIRC fellowship for Italy
- Oxiamo ONLUS
Zitieren
APA
Malighetti, F., Civettini, I., Aroldi, A., Villa, A. M., Villa, M., Sala, L., Cordani, N., Cadamuro, M., Cortinovis, D., Piazza, R., Mologni, L., & Ramazzotti, D. (2026). Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations. Bioinformatics. https://doi.org/10.1093/bioinformatics/btag491
Vancouver
Malighetti F, Civettini I, Aroldi A, Villa AM, Villa M, Sala L, et al. Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations. Bioinformatics. 2026. doi:10.1093/bioinformatics/btag491
BibTeX
@article{Malighetti2026,
author = {Malighetti, Federica and Civettini, Ivan and Aroldi, Andrea and Villa, Alberto Maria and Villa, Matteo and Sala, Luca and Cordani, Nicoletta and Cadamuro, Massimiliano and Cortinovis, Diego and Piazza, Rocco and Mologni, Luca and Ramazzotti, Daniele},
title = {Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations},
journal = {Bioinformatics},
year = {2026},
doi = {10.1093/bioinformatics/btag491}
}
EUVIMED